Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various... see more

Recent & Breaking News (TSXV:TLT)

Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study ("Study II") Progress

ACCESS Newswire July 30, 2020

Theralase Announces Management Information Circular and Annual General Meeting Postponement Due to COVID-19

ACCESS Newswire June 30, 2020

The Top Healthcare Bullboards: April - June 2020

Stockhouse Editorial June 17, 2020

Theralase Release 1Q2020 Financial Statements

ACCESS Newswire May 29, 2020

Massive FDA Green Light for Leading Bladder Cancer Solution

Omri Wallach May 26, 2020

Theralase Receives FDA IND Authorization

ACCESS Newswire May 19, 2020

Theralase Announces Warrant Extension

ACCESS Newswire May 11, 2020

Theralase Releases 2019 Financial Results

ACCESS Newswire April 29, 2020

Theralase Releases Quarterly Newsletter

ACCESS Newswire April 21, 2020

The Top Healthcare Bullboards: Jan - Mar 2020

Stockhouse Editorial March 23, 2020

Theralase Provides Company Update on Phase II Bladder Cancer Clinical Study

ACCESS Newswire March 20, 2020

Advanced Research to Answer Multibillion Dollar Bladder Cancer Problem

Stockhouse Editorial February 28, 2020

Theralase Advances Its Pivotal Phase II Non-Muscle Invasive Bladder Cancer Study with a New Clinical Study Site in Nova Scotia

ACCESS Newswire February 25, 2020

Theralase Technologies Awarded 2020 TSX Venture 50

ACCESS Newswire February 20, 2020

Theralase Granted US Patent for Multiwavelength Photodynamic Therapy

ACCESS Newswire January 27, 2020

Theralase Wins Precedent-Setting Lawsuit Against Anonymous Individuals for Posting Defamatory Comments Online

ACCESS Newswire January 16, 2020

View from the C-Suite: Shawn Shirazi, Chief Executive Officer, Theralase Technologies Inc., tells his company's story. Filmed on December 18, 2019

Canada NewsWire January 8, 2020

Theralase Releases Quarterly Newsletter

ACCESS Newswire January 7, 2020

Theralase Releases Third Quarter 2019 Financial Results and Company Update

ACCESS Newswire November 29, 2019

Theralase Researchers Receive Recognition for Recent Scientific Publications

ACCESS Newswire November 27, 2019